Allist(688578)2024-10-29 09:54Financial Performance - In Q3 2024, the company achieved a revenue of 957 million CNY, a year-on-year increase of 59.73% [5] - The net profit attributable to shareholders was 407 million CNY, reflecting a growth of 101.38% [5] - For the first three quarters of 2024, total revenue reached 2.533 billion CNY, up 87.97% year-on-year [5] - The net profit attributable to shareholders for the same period was 1.063 billion CNY, a significant increase of 158.99% [5] Product Performance - The growth in performance is primarily driven by the continued sales increase of the core product, Furmetinib, which was included in the national medical insurance directory [6] - Sales expenses for the first three quarters were 988 million CNY, with a sales expense ratio of 39.01% [6] - The company has introduced new products, including KRAS G12C inhibitor and SHP2 inhibitor, expanding its oncology pipeline [6] Clinical Research and Development - Furmetinib has shown promising clinical data, with an overall response rate (ORR) of 81.8% in a global Phase Ib study for EGFR PACC mutation non-small cell lung cancer (NSCLC) patients [7] - The company is actively exploring combination therapies with Furmetinib to enhance treatment efficacy [8] - A global multi-center exploratory study for Furmetinib in treating EGFR PACC mutation NSCLC is underway, with over 160 patients enrolled [11] Market Expansion and Strategy - The company anticipates steady growth in new patient numbers due to the inclusion of Furmetinib in the national medical insurance reimbursement list [10] - The sales team is continuously expanding and optimizing, increasing the number of hospitals and doctors covered [11] - The company is also pursuing IND plans for new products, including a new generation of EGFR oral small molecule inhibitors and KRAS G12D inhibitors [17]